Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAPS: Rivaroxaban vs warfarin in high‑risk antiphospholipid syndrome
2013-004575-13Phase 3Terminated
- Sponsor
- Department of Cardiac, Thoracic and Vascular Sciences - University of Padua
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban in antiphospholipid syndrome (APS) (2 arms), sponsored by Department of Cardiac, Thoracic and Vascular Sciences - University of Padua. Primary endpoint: Primary composite outcome. Started Sep 2014; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2013-004575-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004575-13.